Review of 12 months' treatment with L-dopa in Parkinson's disease, with remarks on unusual side effects.
D000328:Adult; D000368:Aged; D001282:Atrial Flutter / Q000139:chemically induced; D001835:Body Weight / Q000187:drug effects; D003680:Deglutition Disorders / Q000139:chemically induced; D003975:Diazepam / Q000627:therapeutic use; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects* / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D004417:Dyspnea / Q000139:chemically induced; D005260:Female; D006801:Humans; D006948:Hyperkinesis / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009155:Mutism / Q000139:chemically induced; D010259:Paranoid Disorders / Q000139:chemically induced; D010300:Parkinson Disease / Q000188:drug therapy*; D010608:Pharyngeal Diseases / Q000139:chemically induced; D010653:Phenylbutazone / Q000627:therapeutic use; D014705:Verbal Behavior / Q000187:drug effects
D004295:Dihydroxyphenylalanine; D010653:Phenylbutazone; D003975:Diazepam